Oncology & Cancer

Clinical validation for LOXO-101 against TRK fusion cancer

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a ...

Oncology & Cancer

Developing new anti-cancer medicines

The prospect of four new cancer medicines becoming a reality for patients has taken a huge step forward with the announcement of a £34M investment by a European private biotech company in University research.

Other

Mallinckrodt buying Cadence Pharma for $1.21B

Health care products company Mallinckrodt is buying Cadence Pharmaceuticals Inc. for about $1.21 billion to help enhance its specialty pharmaceuticals segment.

page 1 from 2